Zometa (zoledronic acid) Injection : Cancer and Your Bones Zometa (zoledronic acid) Injection : Cancer and Your BonesZometa (zoledronic acid) Injection : Novartis Oncology
Zometa (zoledronic acid) Injection : Zometa Information
Zometa (zoledronic acid) Injection : Zometa Reimbursement
Zometa (zoledronic acid) : Bone Metastases Assessment and Measurement
Complications & Incidence
Diagnosis & Monitoring
Benefits in Treating Bone Mets
Zometa (zoledronic acid) Injection : Zometa Resources
Zometa (zoledronic acid) Injection : Prescribing Information
Zometa (zoledronic acid) : Important Safety Information
Zometa (zoledronic acid) Injection : For Zometa Consumers
Zometa (zoledronic acid) : Bone Health Training For Nurses
   


Bone Metastases Complications and Incidence

Percentages of advanced-stage cancer patients with bone metastases worldwide.
Zometa (zoledronic acid) : Bone Metastases Complications and Incidence

52% of breast and prostate cancer patients and 55% of lung cancer patients with bone metastases will develop painful bone complications if left untreated.

 Zometa (zoledronic acid) Injection : Related Links
Mechanism of Action - Bone Metastases
Diagnosis & Monitoring
Bone Health Nurse Program
  

Bone complications include:

  • Pathologic fractures: vertebral and nonvertebral bone fractures that occur spontaneously or following minor trauma
  • Spinal cord compression: Tumor impingement on the spinal cord, causing vertebral compression fractures and/or neurologic impairment
  • Need for radiation or surgery to bone: prevention, palliation, or treatment of lesions, pathologic fractures and spinal cord compression

Bone complications may lead to increased morbidity and reduction of patients’ functional independence.[1,2]
Preventing or delaying bone complications can dramatically improve patients’ outcomes.[3]

Read about bone metastases diagnosis and monitoring.

  1. Delea T, McKiernan J, Liss M, et al. Cost of skeletal complications in patients with bone metastases of solid tumors. Poster presented at the Federation of European Cancer Societies, 12th European Cancer Conference (ECCO 12); September 24, 2003; Abstract 1.056.
  2. Coleman RE. Skeletal complications of malignancy. Cancer. 1997; 80 (suppl): 1588-1594.
  3. Major PP, Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol. 2002;25(6 Suppl 1):S10-8.

 

 
Novartis Pharma US